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Abstract Pancreatic islet β-cell death occurs in type 1
and 2 diabetes mellitus, leading to absolute or relative
insulin deficiency. β-cell death in type 1 diabetes is due
predominantly to autoimmunity. In type 2 diabetes β-cell
death occurs as the combined consequence of increased
circulating glucose and saturated fatty acids together
with adipocyte secreted factors and chronic activation of
the innate immune system. In both diabetes types intra-
islet inflammatory mediators seem to trigger a final com-
mon pathway leading to β-cell apoptosis. Therefore anti-
inflammatory therapeutic approaches designed to block
β-cell apoptosis could be a significant new development
in type 1 and 2 diabetes.
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Introduction
Type 1 diabetes is caused by absolute insulin deficiency
due to destruction of the pancreatic β-cells. The majority
of type 1 diabetes cases are considered to be due to im-
mune mediated β-cell destruction, leaving a small pro-
portion of idiopathic cases in which immune markers
cannot be detected, and which are caused by other patho-
genetic mechanisms such as rare genetic syndromes, 
β-cell lytic virus infections, or environmental toxins [1].
As described below, immune-mediated type 1 diabetes
can be considered to be an inflammatory disease of the
pancreatic islet [2]. The histopathology in recent-onset
type 1 diabetic patients resembles a delayed type 4 hy-
persensitivity reaction, i.e., mononuclear cell infiltration
into the islets and selective β-cell destruction (insulitis)
[3]. Interaction between antigen presenting cells and 
T-cells leads to prolonged presence in high local concen-
trations of inflammatory mediators, for example cyto-
kines, chemokines, reactive oxygen species (ROS), and
other inflammatory products [4]. Thus all islet cells are
exposed to the same inflammatory environment, and al-
though β-cell destruction may not be exclusively specific
(there is also evidence of damage to peri-islet Schwann
cells [5] and some α-cell damage), inherent features of
the β-cell sensitize the β-cell to the destructive abilities
of the inflammatory mediators (see below).
Type 2 diabetes mellitus manifests itself in individuals
who loose the ability to produce sufficient quantities of
insulin to maintain normoglycemia in the face of insulin
resistance [6] (Fig. 1). The contribution of a relative insu-
lin deficiency to the establishment of overt diabetes is
now widely accepted [7, 8, 9, 10]. The ability to secrete
adequate amounts of insulin depends on β-cell function
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Fig. 1 Proposed scheme for the initiation of type 2 diabetes. The
ability to secrete adequate amounts of insulin depends on the pan-
creatic β-cell mass (green spheres). Insulin resistance (stop sign)
increases insulin demand, leading to β-cell proliferation and in-
creased β-cell mass. When β-cell expansion is offset by concomi-
tant apoptosis, a relative insulin deficiency occurs, leading to dia-
betes
and mass. The endocrine pancreas has a remarkable ca-
pacity to adapt to conditions of increased insulin demand,
such as in obesity, pregnancy, cortisol and growth 
hormone excess, by increasing its functional β-cell 
mass; only 10–20% of individuals fail to adapt and 
become diabetic with time [10]. Long-term adaptation of
the β-cell mass to conditions of increased demand in-
volves a balance of β-cell replication and apoptosis as
well as development of new islets from exocrine pancre-
atic ducts [10, 11]. There is controversy whether β-cell
mass, and not only β-cell function, is decreased in type 2
diabetes [6, 12, 13, 14, 15]. These discrepancies are in
part due to difficulty in procuring well-preserved pancre-
as tissue from humans. However, two recent and impor-
tant studies may end the controversy [16, 17]. In particu-
lar, Butler et al. [16] have studied a large sample of well-
preserved pancreases obtained from humans at autopsy.
In nondiabetic controls obesity resulted in an increase in
relative β-cell volume. In contrast, humans with impaired
fasting glucose and type 2 diabetes had a deficit in rela-
tive β-cell volume compared to nondiabetic weight
matched cases. Moreover, the frequency of β-cell apopto-
sis was increased in type 2 diabetes. Taken together these
data imply a central role for a deficit of β-cell mass in the
pathophysiology of type 2 diabetes and suggest that the
underlying mechanism is increased β-cell apoptosis.
Increasing evidence links type 1 and 2 diabetes [18,
19, 20, 21, 22, 23]. Pancreatic β-cell demise by apoptosis
is a common cellular denominator in both diseases in hu-
mans. Although types 1 and 2 diabetes may have etiolog-
ical and pathogenetic differences, β-cell destruction
eventually occurs in both cases, leading to clinical mani-
festation of absolute or relative insulin deficiency. Insu-
lin dependence occurs rapidly in type 1 and following a
prolonged time in type 2 diabetes. This reflects a differ-
ence in the rapidity of β-cell destruction but not in the
hallmark of the diseases: β-cell apoptosis [21]. This may
be compared to cardiac failure: several underlying and
precipitating heart diseases cause the same clinical mani-
festation of heart failure. This contribution reviews the
mechanisms leading to decreased β-cell functional mass
in type 1 and 2 diabetes with a focus on inflammatory
mediators as a possible final common pathway.
Inflammation is defined as the local physiological re-
sponse to tissue injury. It is characterized by cell inva-
sion and local metabolic and circulatory alterations,
sometimes accompanied by functional or structural dam-
age of the invaded tissue. It is not in itself a disease but
rather a manifestation of disease. Inflammation has bene-
ficial effects such as preventing spread of infections.
Equally, it may produce disease by tissue destruction due
to inflammatory mediators, ROS and complement com-
ponents. In this review we describe the involvement of
inflammatory mediators and the signaling pathways acti-
vated by these mediators in pancreatic β-cells to illus-
trate the concept that immunological and metabolic
stressors may converge on common molecular mecha-
nisms leading to β-cell apoptosis in the two main forms
of diabetes.
Inflammatory mediators in type 1 diabetes
Type 1 diabetes is, as noted above, caused by immune
mediated β-cell destruction triggered by environmental
factors in genetically predisposed individuals [24].
Etiology
The following observations support the importance of
the environmental factors in the etiology of type 1 diabe-
tes [24, 25]:
– The concordance rate of type 1 diabetes in monozy-
gotic twin pairs is 30–50%, underlining that at least
50% of the etiology are not explained by genetic fac-
tors.
– Low-risk populations acquire a higher diabetes risk
when migrating to higher incidence areas.
– Rapid increases in diabetes incidence within relative-
ly few years in nonmigratory populations.
– Seasonal variations in diabetes incidence.
– Incidence differences between genetically comparable
populations.
Apart from the congenital Rubella syndrome, where in-
dividuals exposed to Rubella infection in vitro develop
type 1 diabetes later in life [26], it is not at present possi-
ble to pinpoint one particular type of virus as a causal
factor. Much interest has focused on Coxsackie-B virus
infection, particularly in early childhood and in utero. At
present, however, there are no intervention studies to
support antiviral strategies in the prevention of type 1 di-
abetes apart from the Rubella program implemented in
most countries. β-cell toxic substances in certain foods
such as nitrosamines have been accused of predisposing
to type 1 diabetes, but this has not been universally con-
firmed. Other nutritional factors such as early exposure
to cow’s milk protein, gluten, or vitamin D are under in-
vestigation as causal factors. Thus, although environ-
mental factors undoubtedly contribute to the etiology of
type 1 diabetes, there is no ubiquitous factor to the tar-
geted as intervention.
Type 1 diabetes is a polygenic disease [25]. Approxi-
mately 50% of the genetic susceptibility can be explained
by alleles in the HLA class II region, in particular certain
DQ alleles. More than 95% of type 1 diabetic patients
carry these predisposing alleles, but the occurrence of
these alleles in the background population is high, ap-
proximately 50%. It is believed that the diabetes predis-
posing DQ antigens have a shape of the antigen present-
ing groove of the molecule that leads to more efficient
presentation of β-cell associated autoantigens. Genome-
wide scans have identified approximately 15 other loci
linked to type 1 diabetes with only five other loci than the
HLA region found to be associated in three or more of
these genome-wide scans. It has been possible as yet to
identify the nature of only one of these four additional
susceptibility genes, IDDM2, a 5′ variable number of tan-
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dem repeats of the insulin gene. This variation may code
for altered insulin expression in the thymus leading to re-
duced central tolerance against insulin, believed to be one
of the β-cell autoantigens. The nature of the remaining
genetic loci associated with type 1 diabetes has not been
identified. Large international consortia are currently
searching for additional non-HLA diabetes disposing re-
gions and attempting to identify the candidate genes in
these regions and their function. In summary, type 1 dia-
betes is a polygenic disease, the genetic predisposition of
which is carried mostly by DQ antigens of the HLA class
II region. Diabetes predisposing alleles are common vari-
ations in normally functioning genes making antenatal di-
agnosis and gene therapy unlikely as curative strategies.
Pathogenesis of type 1 diabetes
Apart from being associated with immune response
genes the disease is also associated with the occurrence
of other organ specific autoimmune diseases, which oc-
cur three to six times more commonly in type 1 diabetic
patients. These observations support that these diseases
constitute a family of immune mediated disorders. Both
cell-mediated and humoral autoimmunity have been de-
tected in type 1 diabetic patients, and, as noted, recent-
onset type 1 diabetic patients exhibit a mononuclear cell
infiltrate into the pancreatic islets and β-cell destruction
entitled insulitis. More direct evidence for the involve-
ment of the immune system comes from large placebo-
controlled intervention studies using the T-cell immuno-
suppressant cyclosporine A [27, 28]. These studies
showed that immunosuppression induces and maintains
remission and preserves β-cell function throughout the
treatment period with the immunosuppressant. The stud-
ies confirm (a) that the immune system is directly in-
volved in the β-cell destruction and not the consequence
of secondary immune activation to β-cell destruction
caused by other primary factors, and (b) that β-cell mass
can be preserved by intervening in immune functions.
Unfortunately, due to side effects to cyclosporine and
other currently available potent immunosuppressants the
use of immunosuppressive therapy is not clinically feasi-
ble. Immunoregulatory defects have been identified in
animal models and in patients and these defects may
contribute to the loss of self-tolerance and lead to auto-
immune activation. Recent studies using short-term ther-
apy with anti-T-cell intervention (nondepleting anti-CD3
antibodies) have shown positive results [29] that are now
under evaluation in randomized clinically controlled tri-
als. Unfortunately, primary prevention studies using ei-
ther nicotinamide as a β-cell protectant or low-dose sub-
cutaneous intermediate-acting insulin [30] to reduce β-
cell stress have failed to show any benefits in individuals
at risk of developing type 1 diabetes. Therefore much
more needs to be known about the basic mechanisms
leading to β-cell destruction.
More detailed studies of the pathogenetic mechanisms
leading to β-cell destruction in humans have been hin-
dered by the inaccessibility of the human islet tissue
from type 1 diabetic patients. The insulitis lesion can be
detected in most recent onset type 1 diabetic patients in
childhood and adolescents, but it is much more difficult
to detect in older individuals. The insulitis lesion is not
synchronized, and the difficulty in demonstrating insuli-
tis in older type 1 diabetic patients may be due to a slow-
er progressing, more desynchronized β-cell destruction.
Interestingly many patients, particularly those with older
age at onset, have some residual β-cell function left even
many years after the diagnosis. The mechanisms sparing
those β-cells are completely unknown, but may be due to
(a) selection of resistant β-cell populations, (b) a lack of
stimulation of the immune response at a certain threshold
of β-cell antigenic load, (c) immunoregulatory events re-
lating to diabetes duration or therapy. In support of the
latter is the fact that intensive insulin therapy seems to
lead to preserved β-cell function [31]. Since residual 
β-cell function is being associated with improved meta-
bolic control and lower incidence of acute and late dia-
betic complications [32], even intervention that would
rescue the remaining β-cell mass at diagnosis would be
valuable.
For the reasons above, intensive research is being in-
vested into the molecular mechanisms of β-cell destruc-
tion with the aim of developing novel pharmacological
targets.
Effector mechanisms
In humans the insulitis infiltrate carries most types of in-
flammatory cells, i.e., antigen-presenting cells, especial-
ly macrophages, T-helper cells, cytotoxic T-cells, B-lym-
phocytes, and natural killer cells [24]. In animal models
it has been possible to study the sequence of events, and
the first cells to infiltrate the islet are antigen-presenting
cells, followed by T-cells [33]. Although B-lymphocytes
may act as antigen-presenting cells and may be required
for diabetes development in the nonobese diabetic
(NOD) mouse model, diabetes has been observed even
in B-lymphocyte deficient patients, confirming that 
B-lymphocytes are not crucial for development of type 1
diabetes in humans [34]. Antibodies are not considered
to be pathogenetic effectors but rather markers of disease
due to poly-clonal immune activation. There are two
main schools of thought regarding effectors in type 1 di-
abetes: (a) β-cell destruction is mediated by cytotoxic 
T-cells via the T-cell effector mechanisms Fas/Fas-
ligand, membrane-bound TNF, or the perforin/granzyme
system. (b) β-cell destruction is caused mainly by in-
flammatory mediators such as cytokines, which lead to
the induction of apoptosis in β-cells via mechanisms de-
scribed below.
Neither of the two mechanisms alone can be responsi-
ble for complete β-cell destruction. The following obser-
vations argue that T-cells are not sufficient. (a) Destruc-
tion of syngenic islet grafts by disease occurrence in ani-
mal models is independent of cytotoxic T-cells [35, 36].
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(b) In the NOD mouse cytotoxic T-cells are required on-
ly for the first 14 weeks of the pathogenetic process
whereas the later islet destruction is T-cell independent
[37]. (c) A CD4+ helper T-cells clone from insulitis infil-
trate of NOD mice is necessary and sufficient to transfer
disease whereas only very unique T-cell receptor trans-
genic T-cell clones can transfer disease independently of
CD4+ [38]. Similarly cytokines are probably not the sole
mediators of β-cell destruction. (a) Many systemic cyto-
kine knock-outs in the NOD model do not have reduced
diabetes incidence or only partially reduced diabetes in-
cidence [4, 33]. (b) Local overexpression of a number of
cytokines have been insufficient individually to cause is-
let cell destruction in diabetes [4, 33]. Thus most likely
both inflammatory mediators and the T-cell system con-
tribute to β-cell destruction in type 1 diabetes.
It has been shown that cytokines are a prerequisite for
β-cell induction of Fas, thereby sensitizing the β-cell to
T-cell mediated destruction [39]. Cytokines either indi-
vidually or in combinations cause apoptosis in human
and rodent pancreatic β-cells [4, 33]. Since cytokines
therefore seem to be central in both pathogenetic mecha-
nisms described above we deal in detail with cytokine
signaling and molecular effector pathways in β-cells be-
low (see “Signaling and molecular effector pathways”).
Inflammatory mediators in type 2 diabetes
Chronic inflammation has received increasing attention
in recent years as an important pathophysiological mech-
anism in various diseases. Increased release and action
of proinflammatory cytokines are thought to be involved
in insulin resistance and atherosclerosis [40, 41, 42, 43,
44, 45]. Similar mechanisms could also occur in islets of
type 2 diabetics. Indeed, as discussed in the “Introduc-
tion,” a progressive decline in β-cell function and mass
characterizes not only type 1 but also type 2 diabetes. In-
flammatory mediators may induce both impaired β-cell
function and death. Therefore the chronic increase in in-
flammatory mediators observed in type 2 diabetes might
affect not only insulin-sensitive tissues and blood vessel
walls but could also affect pancreatic β-cells. If so, what
are the causes of this increase in inflammatory media-
tors?
Etiology
Type 2 diabetes is influenced genetically, and it occurs in
identical twins with almost total concordance [46]. In
most cases there is evidence that multiple gene defects
influence overall susceptibility to type 2 diabetes [47].
Single gene defects leading to type 2 diabetes have been
identified only in a subgroup of at the most 5%. The best
described monogenic forms are the maturity-onset diabe-
tes of the young. Interestingly, all genes for maturity-on-
set diabetes of the young that have been identified to
date alter glucose sensing or intracellular signaling
events involved in insulin secretion [48, 49, 50], in line
with the concept of a central role for the functional 
β-cell mass (see above). In addition to genetic factors,
development of type 2 diabetes is strongly influenced by
environmental factors, including decreased physical 
activity, nutrition and obesity. This promotes the follow-
ing factors, which are possible mediators of an inflam-
matory process.
Adipocyte-secreted factors
Adipose tissue was long considered a passive tissue
whose role was limited to the storage of fat. Several ob-
servations, however, have now uncovered the endocrine
activity of adipocytes. Locally produced hormones and
cytokines possess important auto-/paracrine properties.
Some are also released into the circulation and have 
endocrine effects. In particular, leptin, TNF-α, interleu-
kin (IL) 6, and IL-1 receptor antagonist (IL-1Ra) are pro-
duced and secreted by fat tissue [51, 52, 53, 54, 55]. In-
terestingly, expression levels of these factors are in-
creased in human obesity and have been causally linked
to insulin resistance. Nevertheless, these factors may af-
fect not only insulin-sensitive tissues but also act on oth-
er cells including the pancreatic β-cells.
Increased cell nutrients
Obesity is associated with changes in the plasma levels
of cell nutrients. Plasma free fatty acid (FFA) levels are
permanently increased in obesity. Moreover, insulin re-
sistance diminishes glucose uptake, resulting in transient
postprandial hyperglycemic excursions. This mild hyper-
glycemia could act on the β-cells even before diabetes
manifests itself or at the very early stages of the disease.
Therefore both nutrients, FFAs and glucose, may inter-
fere with β-cell turnover and function influencing the on-
set and course of diabetes.
Innate immune system
Innate immunity is considered to provide rapid host de-
fenses until the slower adaptive immune response devel-
ops [56, 57, 58]. These responses comprise the release of
acute-phase proteins such as C-reactive protein, hapto-
globin, fibrinogen, plasminogen activator inhibitor and
serum amyloid A. A number of studies have reported in-
creased acute-phase proteins in type 2 diabetes [44, 45,
57, 59, 60, 61, 62, 63]. It is unclear why the innate im-
mune system is activated in type 2 diabetics. Possibly it
is induced by overnutrition, altered nutrition, and insulin
deficiency and facilitated by genetic predisposition.
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Autoimmunity
In 1997 the Expert Committee of the American Diabetes
Association introduced a new classification of diabetes
based on etiological considerations [1]. The class termed
type 1 diabetes includes the vast majority of cases that
are due primarily to pancreatic islet β-cell destruction, in
particular the cases attributable to an autoimmune pro-
cess. However, 10–15% of subjects originally diagnosed
with type 2 diabetes are cases of “cryptic” type 1 diabe-
tes or evolve with time to a type 1 state and exhibit anti-
β-cell autoimmunity [18, 19, 20, 21, 22, 23], referred to
as latent autoimmune diabetes in adults [64, 65]. Fur-
thermore, and as discussed above, an ongoing process of
β-cell destruction by apoptosis is not limited to type 1
diabetes but has also been described in animal models of
type 2 diabetes and in human type 2 diabetics [16, 66].
In turn, apoptotic cells can provoke an immune response
[67, 68]. Moreover, innate immunity may determine to
which antigens the acquired immune system responds
[69]. Therefore the activation of the innate immune
system observed in type 2 diabetics (see above) may pre-
dispose to islet cell autoimmunity. Finally, hyperglyce-
mia by itself induces β-cell-expression of several mole-
cules involved in immunological processes, for example,
IL-1β and Fas [22, 23]. Therefore the innate immune
system may serve functions outside the classical immune
framework as determinants of diseases not traditionally
conceived to be autoimmune, i.e., atherosclerosis, osteo-
porosis, and type 2 diabetes. Thus many cells other than
immune cells produce inflammatory mediators.
Mediators
Based on the above, secretory products of the adipo-
cytes, FFA, glucose, the innate and adaptive immune
system may all be mediators of the ongoing process of 
β-cell destruction occurring in type 2 diabetes. We now
discuss the potential individual contribution of each of
these factors in this process.
Adipocyte-secreted factors
Leptin is expressed primarily in the adipose tissue and
therefore represents the most obvious exponent of the
adipocyte. In rodent islets leptin induces β-cell prolifera-
tion and protects from FFA-induced β-cell apoptosis [70,
71, 72, 73]. On the other hand, chronic exposure of hu-
man islets to leptin leads to β-cell apoptosis (K. Maedler
and M.Y. Donath, manuscript in preparation). Thus it re-
mains to be clarified whether leptin predominantly links
obesity to islet hyperplasia or to β-cell apoptosis. TNFα,
in combination with other cytokines, accelerates dys-
function and destruction of the β-cells [4, 74]. However,
it is unclear whether adipose tissue releases sufficient
amounts of TNFα into the circulation [53]. In contrast,
IL-6 released by adipocytes may be responsible for the
increases in plasma IL-6 concentrations observed in obe-
sity [75], and, at least in combination with other cyto-
kines, IL-6 has cytotoxic effects on β-cells [76] and syn-
ergizes with IL-1 in this respect [77].
Increased cell nutrients
Increased FFA levels per se are known to be toxic for 
β-cells, leading to the concept of lipotoxicity [78, 79, 80,
81]. Depending on the food consumed, the ratio of satu-
rated to unsaturated FFA varies, leading to distinct ef-
fects. Thus, saturated FFA are highly toxic whereas un-
saturated FFA may prevent these deleterious effects [82,
83, 84, 85, 86]. The toxic effect of FFA is mediated via
formation of ceramide, increased nitric oxide production
and activation of the apoptotic mitochondrial pathway
[85, 86, 87]. Thus, lipotoxicity may play an important
role in the process of β-cell destruction, but it does not
seem to involve an inflammatory process. Elevated glu-
cose concentrations induce β-cell apoptosis in cultured
islets from diabetes-prone Psammomys obesus, an ani-
mal model of type 2 diabetes [66], in human islets [23,
88] and at higher concentrations in rodent islets [66, 85,
89]. In human islets glucose-induced β-cell apoptosis
and dysfunction are mediated by β-cell production and
secretion of IL-1β [22]. Furthermore, chronic hypergly-
cemia increases production of ROS, which may cause
oxidative damage in β-cells [90, 91, 92, 93, 94]. Both
IL-1β and ROS activate the transcription factor nuclear
transcription factor (NF) κB, which plays a critical role
in mediating inflammatory responses.
Innate immune system
In addition to the endocrine activity of the adipocytes 
described above, macrophages and endothelium may
contribute to increase serum levels of IL-1β, IL-6, and
TNFα in type 2 diabetic patients [57]. These cytokines
induce the liver to produce acute-phase proteins. Simi-
larly, these cytokines may act on the pancreatic islets and
impair β-cell secretory function.
Autoimmunity
Apoptotic cells can provoke an immune response under
appropriate conditions, for example, when present in
high enough numbers or when apoptosis is the conse-
quence of exposure to cytokines such as IL-1β and TNF-
α [18, 67, 68]. Moreover, a pronounced activation of the
acute-phase response is associated with islet cell autoan-
tibodies in patients with type 2 diabetes [19]. Following
glucose- and FFA-induced β-cell apoptosis it is conceiv-
able that depending on age and on genetic and/or envi-
ronmental factors, some type 2 diabetics may show mo-
bilization of T cells reactive to β-cells antigens, culmi-
nating in autoimmune destruction of β-cells similar to
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that observed at earlier stages in “classical” type 1 dia-
betics. This response may be so discrete and desynchro-
nized in time and space that it has evaded detection in
earlier autopsy studies. Clearly, additional studies need
to be conducted to evaluate this notion.
Effector pathways
As described above and illustrated in Fig. 2, the number
of potential β-cell-aggressors resulting from obesity is
impressive. However, it is probable that most of the
above-mentioned cell death mediators have also physio-
logical effects depending on concentrations and duration
of exposure. This is certainly true for glucose and FFA.
In addition to their role as cell nutrients, elevated glu-
cose concentrations and FFA have a dual effect on β-cell
turnover. Depending on duration of exposure to glucose
or FFA and on the genetic background of the islets, glu-
cose and FFA may induce or impair β-cell proliferation
and have pro- or antiapoptotic effects [10, 23, 66, 85, 86,
88, 89, 95]. The expression level of pivotal intracellular
factors may explain these dual effects. For example, the
naturally occurring caspase-8 inhibitor referred to as
Fas-associated death domain-like interleukin-1β convert-
ing enzyme inhibitory protein (FLIP) switches glucose
signaling in human pancreatic β-cells from apoptosis to
cell replication [96]. In turn, the proportion of saturated
vs. unsaturated fatty acids determines the distinct effects
of FFA on the mitochondrial apoptotic pathway [85, 86].
Similar dual effects have been observed for IL-1β, NF-
κB, and NO [4, 74, 97]. This illustrates the complexity
of the intracellular signaling pathway. On the other hand,
several signaling pathways, relevant for type 1 and 2 dia-
betes, converge toward common effectors. This is true
for glucose-induced IL-1β, for TNFα, Fas, NF-κB, and
caspase activation.
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Fig. 2 Inflammatory mediators in type 2 diabetes. Cell nutrients
(glucose and FFA) have direct and indirect effects on β-cells. Ele-
vated glucose concentrations induce β-cell production of IL-1β
leading to β-cell apoptosis. Increased FFA concentrations may af-
fect the viability of the β-cells directly or via obesity, i.e., adipo-
cyte secreted cytokines (TNFα, IL-6, and leptin) may act directly
on the β-cells or activate the innate immune system. The precise
role of the innate and acquired immune system in the ongoing pro-
cess of β-cell demise in type 2 diabetics remains to be investigated
Signaling and molecular effector pathways
As noted above, evidence favors that apoptosis is the
dominant form of β-cell death in both animal models of
diabetes and in humans. Two principal apoptotic path-
ways exist: the “intrinsic” pathway (initiated by the mi-
tochondria) and the “extrinsic” pathway (initiated by cell
surface receptors; Fig. 3). It is likely that both of these
apoptotic pathways are involved in the demise of β-cells
in type 1 and 2 diabetes, although the relative contribu-
tion of each is not clear. As outlined above, pro-inflam-
matory cytokines, and in particular IL-1β, are thought to
be important pathogenic effectors responsible for the in-
duction β-cell apoptosis in both types of diabetes.
Three main cytokines most likely act in synergy dur-
ing the immune infiltration of the pancreas to induce β-
cell damage and apoptosis in type 1 diabetes: IL-1β,
TNFα, and interferon (IFN) γ. IL-1β is secreted by acti-
vated macrophages and, paradoxically, under some cir-
cumstances by β-cells [22, 98]. TNFα is solely produced
and secreted by macrophages, whereas IFNγ is secreted
by T-helper cells. In vitro, IL-1β is the most β-cell cyto-
toxic cytokine sufficient to cause inhibition of β-cell
function and often sufficient to promote an apoptotic re-
sponse. However, massive induction of apoptosis in β-
cells usually requires a combination of IL-1β plus IFNγ
and/or TNFα. Whether IL-1β alone is sufficient to evoke
apoptosis in human β-cells is controversial. Neverthe-
less, several studies have pointed to the fact that IL-1β
alone does induce apoptotic death of human β-cells [22,
23, 99, 100, 101, 102].
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Fig. 3 Overview of cytokine signaling leading to β-cell apoptosis.
Following IL-1β binding to IL-1R1 and docking of IL-1AcP,
MyD88 is recruited to the receptor complex. MyD88 interacts
with IRAK, allowing the binding of TRAF6 to IRAK. TRAF6
causes activation of the MAP/SAPK pathways through ECSIT,
and activation of the NFκB pathway via TAK1-mediated activa-
tion of IKK. IL-1β also stimulates activation of PKCδ possibly
through phospholipase C generation of diacylglycerol. IFNγ bind-
ing to IFN receptor 1 leads to recruitment of IFN receptor 2. Both
IFN receptor types are associated with JAKs, which are activated
by auto- and transphosphorylation upon formation of receptor-li-
gand complexes. JAK2-mediated phosphorylation of STAT1 leads
to STAT1 homodimerization and translocation of the dimers to the
nucleus. TNFα signals through trimerized p60 receptors which via
the DD in the receptors interact with TRADD. FADD is then re-
cruited via TRADD thus allowing binding of receptor-interacting
protein (RIP) and TRAF2 to the receptor complex. TRAF2 acti-
vates NFκB through NFκB-inducing kinase (NIK)-IKK and acti-
vates the JNK/p38 pathways. The figure highlights the importance
of the NFκB and the MAP/SAPK signaling pathways as key com-
ponents in mediating cytokine-induced β-cell apoptosis
IL-1 signaling
IL-1β signal transduction is initiated by ligand binding
to type 1 IL-1 receptor (IL-1R1) allowing docking of the
IL-1R accessory protein (IL-1AcP). Following this, IL-
1R activated kinase (IRAK) is recruited to the receptor
complex via the adaptor protein MyD88. IRAK then in-
teracts with and activates TNF receptor associated factor
(TRAF) 6 [103]. Signaling events downstream TRAF6
include the activation of the evolutionary conserved sig-
naling intermediate in Toll/IL-1 pathways (ECSIT),
which activates mitogen-activated protein (MAP) kinase
(MAPK)/extracellular signal-regulated kinase (ERK) ki-
nase kinase (MEKK) 1. MEKK-1 activation can lead to
activation of the group of MAP/stress-activated protein
kinases (MAP/SAPK) as well as NFκB [104].
MAP/SAPKs, which comprise ERK, p38, and c-jun N-
terminal kinase (JNK), are activated in three-kinase
modules or cascades which are often controlled by the
action of scaffold proteins. Activated MAP/SAPKs are
able to phosphorylate a broad spectrum of cellular pro-
teins including transcription factors of the activator pro-
tein 1 family. Active TRAF6 also causes activation of in-
hibitory κB protein (IκB) kinase (IKK) through TAB-1
and transforming growth factor β-activated kinase 1
(TAK-1) [105, 106]. This leads to phosphorylation of
IκB, a cytosolic inhibitor of NFκB. Phosphorylation tar-
gets IκB for ubiquitination and degradation, thus freeing
NFκB to translocate to the nucleus and regulate the tran-
scription of target genes [103]. In addition to activation
of these two main and general IL-1β-activated pathways,
both of which are strongly activated by IL-1β in β-cells,
IL-1β also activates protein kinase C (PKC) δ in β-cells
[107]. As detailed below, the MAP/SAPK, NFκB, and
PKC-δ pathways have individually been linked to the
apoptotic response in β-cells.
One IL-1β-induced (late) event that has gained much
attention is the induction of expression of inducible ni-
tric oxide synthase (iNOS). IL-1β stimulation of this en-
zyme occurs after approx. 4–6 h and results in massive
production of reactive NO. Although the precise role and
contribution of NO in β-cell killing remain unclear, it is
generally believed that NO accounts for some of the del-
eterious effects of IL-1β in rodent β-cells, whereas NO is
dispensable for cytokine-induced human β-cell apoptosis
[4, 108]. NFκB seems to be an absolute requirement for
cytokine-induced iNOS expression in both rodent and
human β-cells [109, 110, 111, 112], but the promoter for
iNOS contains multiple potential binding sites for other
transcription factors including activator protein 1 and
signal transducer and activator of transcription (STAT,
see below), suggesting that a number of different path-
ways regulate iNOS transcription. In support of this is
that iNOS cannot be induced by IL-1β alone in human
islets, but requires a cocktail of cytokines [22, 76, 110,
113, 113].
IFNγ signaling
IFNγ signaling seems more linear and simple than IL-1
signaling. IFNγ binds to IFNγ receptor 1 which leads to
receptor dimerization and subsequent recruitment of two
membrane-associated accessory proteins, the IFNγ re-
ceptor 2. On the cytoplasmic side the IFNγ receptors are
associated with the Janus tyrosine kinases (JAK) 1 and 2.
When brought into proximity following receptor com-
plex formation, JAK1/2 are activated by auto- and trans-
phosphorylation. Following this, STAT1 molecules bind
to the IFNγ receptor 1 and are subsequently phosphory-
lated by JAK2. Phosphorylated, activated STAT1 then
homodimerizes, translocates to the nucleus and binds to
DNA at γ-activated sites. Further, STAT1 binds and acti-
vates members of the interferon regulatory factor (IRF)
family of transcription factors [114, 115]. IFNγ activa-
tion of STAT1 has been demonstrated in both insulin-se-
creting cells and primary islet cells [116, 117]. Further, it
has been shown that IFNγ induces upregulation of IRF-1
expression in insulin-producing cells [118], and this in
combination with the observation that IFNγ-induced
mRNA expression of IL-1 converting enzyme (caspase-
1) is abrogated in IRF-1−/− mouse islets [119] suggests
that IRF-1 plays an important role in IFNγ signaling in
β-cells. IFNγ neither stimulates nuclear translocation and
DNA binding of NFκB in β-cells nor affects NFκB acti-
vation by IL-1β [118]. In some cells IFNγ activates ERK
MAPK through JAK [114], but this does not seem to be
the case in β-cells. In fact, IFNγ may even lead to de-
creased constitutive MAP/SAPK activities in rat islets
[120].
TNFα signaling
TNF signals through two different receptors, p60 and
p80. The p60 receptor is expressed on all cell types,
whereas expression of the p80 receptor is restricted pri-
marily to cells of the immune system and endothelial
cells. The two receptors have similar extracellular do-
mains but dissimilar intracellular domains. The intracel-
lular part of the p60 receptor contains a so-called death
domain (DD), which lacks the p80 receptor [121]. It is
well established that TNF activates multiple signaling
pathways. The DD of the activated p60 receptor interacts
with the DD-containing protein TNF receptor associated
death domain (TRADD), which in turn recruits Fas-asso-
ciated death domain (FADD). This leads to binding of
TRAF2 and a receptor-interacting protein to the
p60/TRADD/FADD complex. Down-stream signals
from these early signaling events include activation of
phospholipases and sphingomyelinases (resulting in gen-
eration of arachidonic acid/diacylglycerol and ceramide,
respectively), activation of NFκB through NFκB-induc-
ing kinase, and stimulation of the JNK and p38
MAP/SAPK pathways. In addition to these signaling
pathways that are also activated by IL-1β, TNF is capa-
ble of directly activating the apoptotic execution pro-
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gram by activating a caspase cascade triggered by FADD
activation of caspase-8 [121]. However, caspase activa-
tion by TNFα does not seem to be induced in β-cells, as
TNFα alone fails to cause impairment of β-cell function
[122, 123]. In contrast, TNFα stimulation of MAP/
SAPK activation in rat islets [120] and induction of
NFκB in insulin-producing cells have been demonstrated
[124].
The effector pathways
MAP/SAPKs
Studies on insulin-secreting cells and primary β-cells
have revealed that IL-1β is a potent activator of the
MAP/SAPKs ERK, p38, and JNK [125, 126, 127]. The
functional roles of ERK and p38 in IL-1β signaling in β-
cells have been investigated using pharmacological in-
hibitors. These studies showed that both ERK and p38
are required for IL-1β-induced expression of iNOS
[125]. Subsequent studies revealed that blocking ERK or
p38 partially (approx. 25 and 40%, respectively) de-
creased cytokine-induced apoptosis in primary β-cells
[112, 128]. Thus, although it is not clear how ERK and
p38 are involved in promoting iNOS expression and ap-
optosis, these two MAPKs are involved at least to some
degree in mediating β-cell apoptosis upon cytokine ex-
posure. More convincing results have been obtained on
the role of JNK in controlling IL-1β-mediated apoptosis.
Transfection experiments and the use of cell-permeable
peptide inhibitors have demonstrated that inhibiting the
JNK pathway confers almost full protection against ap-
optosis induced by IL-1β in insulin-secreting cells [129,
130, 131]. The protective effect of blocking JNK awaits
to be confirmed in primary β-cells. However, a recent
study suggested that JNK is also a critical component in
oxidative stress-induced suppression of insulin gene
transcription in primary islet cells [132]. The same study
reported that transplantation of streptozotocin-induced
diabetic nude mice with islets infected with dominant
negative JNK expressing adenovirus preserved the insu-
lin gene expression in islet grafts. Further, in these ani-
mals hyperglycemia was ameliorated compared with
control mice. Hence together these findings support an
important role for JNK in the regulation of β-cell func-
tion and death.
Given the fact that IFNγ and TNFα strongly potenti-
ate the cytotoxic effects of IL-1β on β-cells, it is of note
that these two cytokines synergistically augment IL-1β
induced signaling via MAP/SAPKs in rat islets [120].
This observation may provide at least a partial explana-
tion at the signaling level for the synergistic toxic effects
of cytokines on β-cells.
What makes the β-cell so sensitive to proinflammato-
ry cytokines? Transfection of a glucagon-producing rat
cell line with the pancreatic duodenal homeobox factor
(Pdx) 1 transcription factor leading to an insulin-produc-
ing β-cell phenotype results in higher sensitivity to cyto-
kine toxicity [133] and is correlated with higher
MAP/SAPK activation upon treatment with IL-1β [129].
This suggests that enhanced susceptibility to proapoptot-
ic stimuli and signaling is a direct consequence of β-cell
differentiation, and this is potentially the answer why β-
cells are so vulnerable to cytotoxic stimuli and in partic-
ular cytokines. Interestingly, while Pdx-1 seems to
“code” for higher proapoptotic JNK signaling, JNK at
the same time is able to inhibit Pdx-1 DNA binding upon
oxidative stress [132], which would lead to suppression
of β-cell functions. This further supports a strong rela-
tionship between Pdx-1 (and thus the β-cell phenotype)
and JNK in β-cells. Hence JNK is possibly a key media-
tor and regulator of β-cell fate and may therefore repres-
ent an attractive therapeutic target for preservation of β-
cell function and mass in diabetes.
Recently it was demonstrated that JNK activity is ab-
normally elevated in liver, fat, and muscle in dietary and
genetic mouse models of obesity [134]. Also, JNK1−/−
mice on a high fat diet had lower body weight, blood
glucose, and plasma insulin levels than control (JNK1+/+)
mice on high fat diet which were obese, hyperinsuline-
mic, and hyperglycemic. Hence in diabetes JNK may not
only be a crucial factor in the β-cell but also play a sig-
nificant role in mediating obesity and insulin resistance.
NFκB
The involvement of NFκB in cytokine-induced β-cell
death was recently elucidated by adenoviral gene trans-
fer of a nonphosphorylatable and thus a nondegradable
form of IκB, the so-called IκB superrepressor. Infection
of primary purified rat β-cells with adenovirus contain-
ing the IκB superrepressor resulted in decreased apoptot-
ic (and necrotic) cell death induced by a combination of
IL-1β and IFNγ [135]. Similarly, experiments with hu-
man islets have shown that NFκB inhibition by the IκB
superrepressor protects against IL-1β-stimulated, Fas-
triggered apoptosis [136]. Hence there is no doubt that
NFκB plays an important role in cytokine-induced β-cell
apoptosis. What are the target genes of NFκB in β-cells?
The use of novel high-density oligonucleotide arrays has
provided an important tool to investigate the expression
pattern of thousands of genes in parallel. Of the approx.
200 genes whose expression is altered by 24-h exposure
to IL-1β plus IFNγ [137] 66 have been found to be regu-
lated by NFκB in cytokine-treated in primary rat β-cells.
Among these are genes encoding transcription factors,
glucose transporters, and proteins involved in signal
transduction [109]. The relative importance of each of
the NFκB-regulated genes is not clear, but it is likely that
it is the sum of the up- and downregulation of the multi-
ple genes that drives the β-cell into an apoptotic re-
sponse.
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PKC-δ
Recent work has provided evidence for a role of PKC-δ
in IL-1β-mediated β-cell death. IL-1β was shown to in-
duce rapid PKC-δ, but not PKC-α, translocation to the
plasma membrane in insulin-secreting cells [107]. Using
both a pharmacological PKC inhibitor and overexpres-
sion of a kinase dead PKC-δ mutant it was shown that
IL-1β stimulated iNOS expression and NO production
were drastically inhibited. The effect of PKC-δ on iNOS
expression was seemingly due to PKC-δ dependent sta-
bilization of iNOS mRNA [107]. A subsequent study ob-
served that cells containing kinase dead PKC-δ were
protected against IL-1β-induced apoptosis [138].
Calcium
As in other cell types, the role of Ca2+ in the apoptotic
process in β-cells has gained attention, and a number of
studies have demonstrated that Ca2+ is a key player in β-
cell apoptosis. When β-cells are incubated with serum
from type 1 diabetes patients, they undergo apoptosis in
a manner dependent on Ca2+ signaling via L-type volt-
age-gated channels [139]. Further, β-cell apoptosis in-
duced by high glucose or a potassium channel inhibitor
(tolbutamide) can be prevented by blocking L-type Ca2+
channels [89]. Cytokine-induced apoptosis also seems to
involve Ca2+. It has been shown that IL-1β following a
2-h exposure stimulates a cellular net-uptake of Ca2+ via
L-type voltage-gated Ca2+ channels in rat islets [140],
and blocking L-type Ca2+ channels suppresses IL-1β-me-
diated islet cell apoptosis [141]. Further, chronic expo-
sure of mouse islets to a combination of IL-1β and IFNγ
induces an increase in the activity of T-type Ca2+ chan-
nels, resulting in a threefold higher sustained plateau of
cytosolic Ca2+, which is associated with apoptosis [142].
Interestingly, β-cells from NOD mice have been found to
have abnormally higher activity of T-type Ca2+ channels
and higher cytosolic free Ca2+ concentration than control
mouse β-cells [143]. In further support of a role of Ca2+
in mediating cytokine-induced apoptosis is the finding
that calbindin-D28k, a cytosolic Ca2+-binding protein(which at the mRNA level is downregulated by cyto-
kines [109]), protects insulin-secreting cells from apop-
tosis induced by a mixture of IL-1β, IFNγ, and TNFα
[144]. Thus, a substantial amount of evidence suggests a
role for Ca2+ in β-cell apoptosis, although the molecular
mechanisms behind Ca2+-mediated β-cell apoptosis re-
main to be described. We have recently explored the role
of Ca2+ in the regulation of proapoptotic IL-1β signaling
and found that Ca2+ entering through L-type Ca2+ chan-
nels regulates IL-1β activation of MAP/SAPKs (J. Stør-
ling and T. Mandrup-Poulsen, manuscript in prepara-
tion). Therefore one (but probably not the only) role of
Ca2+ could be to amplify and prolong proapoptotic
MAP/SAPK signaling.
Another event which is related to cellular handling of
Ca2+ and which is associated with apoptosis in β-cells is
the depletion of Ca2+ from the endoplasmic reticulum
(ER). Inhibition of sarco-/endoplasmic reticulum Ca2+
ATPase (SERCA), which results in release of Ca2+ from
the ER, induces apoptosis in insulin-producing cells
[145]. The effect of SERCA inhibition on apoptosis does
not seems to be caused by an increase in cytosolic Ca2+,
but is likely to be due to the sustained depletion of ER
Ca2+ [145]. Such a depletion of ER Ca2+, which perturbs
the function of the ER, is well known in many cell types
to give rise to a condition known as ER stress. Interest-
ingly, it has recently been suggested that the ER is a tar-
get of NO in β-cells as NO was found to cause depletion
of ER Ca2+ [146, 147]. Further, cytokines have been
shown to cause downregulation of SERCA at the mRNA
level in β-cells [109, 137]. Together, these observations
suggest that β-cells exposed to cytokines are impaired in
their ability to maintain an adequate level of Ca2+ within
the ER leading to ER stress. Although the transcription
factor C/EBP homologous protein is induced by ER
stress and shown to be involved in mediating ER stress-
induced β-cell apoptosis [146], we have data to suggest
that the JNK signaling pathway is also induced by ER
stress in insulin-secreting cells (J. Størling and T. 
Mandrup-Poulsen, manuscript in preparation).
Fas
The apoptosis-inducing receptor Fas (also known as
CD95 or APO-1) is a member of the TNF receptor su-
perfamily. As with the TNF p60 receptor, Fas has a DD
in the intracellular part of the receptor that is responsible
for the transduction of the apoptotic signal. Activation of
Fas is triggered by Fas ligand (FasL), which exists both
in a soluble and in a membrane-bound form [148], the
former being a weak activator. FasL stimulation of Fas
induces trimerization of the Fas receptor which through
the DD recruits caspase-8 via the FADD/mediator of re-
ceptor induced toxicity (MORT) 1 adaptor. This causes
activation of caspase-8, which in turn triggers a cascade
of down-stream caspases resulting in proteolytic cleav-
age of critical cellular components including lamins and
actin [148]. Normally β-cells do not express Fas but do
so after exposure to cytokines rendering them suscepti-
ble to FasL-induced apoptosis [39, 100, 149, 150]. Also,
exposure of human β-cells to high concentrations of glu-
cose induces upregulation of Fas expression and causes
apoptosis by Fas receptor interaction with constitutively
expressed FasL on neighboring β-cells [23]. However,
Fas receptor signaling may not only be connected to ap-
optosis but also implicated in proliferative signals. Thus
proliferation of human T-cells induced by T-cell receptor
activation is augmented by FasL [151] and T-cells ex-
pressing dominant negative FADD/MORT1 have inhibit-
ed T-cell receptor induced proliferation [152]. What de-
termines whether Fas signaling leads to apoptosis or pro-
liferation? FLIP seems to direct Fas signaling from apop-
tosis into survival/proliferation. In human β-cells FLIP is
constitutively expressed but is downregulated by high
465
glucose. Overexpression of FLIP switches glucose-in-
duced, Fas-mediated β-cell apoptosis into proliferation
in a manner totally dependent on Fas signaling [96], in-
dicating that Fas signaling in the presence of FLIP is
connected with cell replication and survival in β-cells.
The molecular link(s) between FLIP and cell prolifera-
tion have been investigated in T-cells. In these cells FLIP
has been shown to stimulate the NFκB and the ERK
MAPK pathways, which leads to production of the T-cell
growth factor IL-2 [151]. The mechanism(s) underlying
Fas-induced, caspase-8/FLIP-mediated proliferative sig-
naling in β-cells is currently not known but may poten-
tially involve altered NFκB and/or MAP/SAPK signal-
ing. However, regardless the mechanisms involved, it
appears that Fas is not simply a death receptor but a key
regulator of cell cycle which may induce cell death or
proliferation depending on intracellular cofactors.
Inflammatory mediators in type 1 and 2 diabetes:
how can we extinguish the flame burning the 
β-cells?
The first indirect indication that diabetes mellitus has in-
flammatory components was reported in a contribution
in 1876 to the predecessor of the Journal of Molecular
Medicine, the Berliner Klinische Wochenschrift, in
which Professor Ebstein observed that high doses of so-
dium salicylate improves glucosuria in diabetic patients
[153, 154]. Salicylate prevents the activation of NF-κB,
a mediator of inflammation and apoptosis [155]. Another
clinical hint to the role of inflammatory mediators in the
pathogenesis of type 2 diabetes has been recently report-
ed [156]. A prospective study showed that a specific pat-
tern of cytokines is associated with an increased risk of
developing type 2 diabetes. In particular, participants
with a elevation in both IL-6 and IL-1β had a threefold
increased risk of developing diabetes compared to the
reference group. Interestingly, participants with elevated
levels of IL-6 alone and undetectable levels of IL-1β had
no increase in diabetes risk, suggesting the central role
of IL-1β. It is likely that part of those observations are
related to changes in insulin resistance and not only in 
β-cell function [157, 158]. Nevertheless, based on cur-
rent thinking, modulation of the intra-islet inflammatory
mediators in type 1 and 2 diabetes appears as a promis-
ing approach. The progressive decline in functional 
β-cell mass observed in diabetic patients may thus be
prevented and even reversed. Several drugs are in use for
the management of diabetics with the primary aim to
prevent its complications, for example, statins, but not to
improve β-cell function. One can speculate that the
strong anti-inflammatory effects of these drugs are par-
tially responsible for the improved outcome of diabetic
patients, which cannot be explained solely by the lipid-
lowering effects [159]. However, it will probably take
several years until drugs are available with the primary
aim of preventing the inflammatory process of islets. In
the meantime, implementing insulin therapy at early
stages of not only type 1 but also type 2 diabetes appears
reasonable. Insulin has strong antiapoptotic effects and
seems to lead to preserved β cell function (see above).
Although current evidence does not support that insulin
treatment in risk individuals of type 1 diabetes develop-
ment is of benefit [30], it does not rule out that other ap-
proaches with different timing, doses and sites of appli-
cation could be successful. Until then, understanding that
the functional β-cell mass is, relatively or absolutely, de-
creased in most diabetic patients justifies the replace-
ment of what is missing: insulin!
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